Get the Stockscreener App
10.26
4.25%
-0.455
Tempest Therapeutics Inc stock is traded at $10.26, with a volume of 47,213.
It is down -4.25% in the last 24 hours and up +16.40% over the past month.
Tempest Therapeutics Inc is a late-stage develpment biotechnology company developing small molecule therapeutics to treat cancer through mechanisms that directly kill tumor cells and activate tumor-specific immunity. Its clinical-stage therapeutic product candidates are TPST-1120 and TPST-1495 which are clinical-stage molecules designed to inhibit their respective targets.
See More
Previous Close:
$10.71
Open:
$10.78
24h Volume:
47,213
Relative Volume:
0.50
Market Cap:
$45.53M
Revenue:
-
Net Income/Loss:
$-43.10M
P/E Ratio:
-1.0605
EPS:
-9.67
Net Cash Flow:
$-36.82M
1W Performance:
-6.69%
1M Performance:
+16.40%
6M Performance:
-2.95%
1Y Performance:
-40.69%
1-Day Range:
$10.22
$11.02
1-Week Range:
$10.22
$11.18
52-Week Range:
$5.3495
$20.67
Tempest Therapeutics Inc Stock (TPST) Company Profile
Name
Tempest Therapeutics Inc
Sector
Industry
Phone
415-798-8589
Address
2000 SIERRA POINT PARKWAY, BRISBANE
Compare TPST with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
TPST
Tempest Therapeutics Inc
|
10.26 | 46.64M | 0 | -43.10M | -36.82M | -9.67 |
|
VRTX
Vertex Pharmaceuticals Inc
|
394.53 | 99.62B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
465.89 | 61.52B | 2.46B | -319.09M | -52.09M | -2.47 |
|
REGN
Regeneron Pharmaceuticals Inc
|
560.00 | 58.91B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ARGX
Argen X Se Adr
|
756.38 | 46.69B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
324.34 | 34.54B | 3.81B | -644.79M | -669.77M | -6.24 |
Tempest Therapeutics Inc Stock (TPST) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-10-25 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Apr-10-25 | Downgrade | Scotiabank | Sector Outperform → Sector Perform |
| Mar-14-24 | Initiated | Scotiabank | Sector Outperform |
| Feb-08-24 | Initiated | Jefferies | Buy |
Tempest Therapeutics Inc Stock (TPST) Latest News
Can volume confirm reversal in Tempest Therapeutics Inc.Market Trend Review & Low Drawdown Trading Techniques - Newser
Visualizing Tempest Therapeutics Inc. stock with heatmapsProfit Target & Free Growth Oriented Trading Recommendations - Newser
Analyzing Tempest Therapeutics Inc. with risk reward ratio chartsTrade Performance Summary & Comprehensive Market Scan Reports - Newser
Does Tempest Therapeutics Inc. qualify in momentum factor screening2025 Risk Factors & Long-Term Growth Portfolio Plans - Newser
Price momentum metrics for Tempest Therapeutics Inc. explained2025 Trading Volume Trends & Comprehensive Market Scan Insights - Newser
How to manage a losing position in Tempest Therapeutics Inc.Inflation Watch & Expert Approved Trade Ideas - Newser
Will Tempest Therapeutics Inc. price bounce be sustainableMarket Risk Report & AI Powered Market Trend Analysis - Newser
Real time pattern detection on Tempest Therapeutics Inc. stockInflation Watch & Low Volatility Stock Recommendations - Newser
Market reaction to Tempest Therapeutics Inc.’s recent newsProduct Launch & Verified High Yield Trade Plans - Newser
Backtesting results for Tempest Therapeutics Inc. trading strategies2025 Volume Leaders & Daily Price Action Insights - Newser
Is Tempest Therapeutics Inc. reversing from oversold territoryJuly 2025 Fed Impact & Safe Investment Capital Preservation Plans - Newser
Predicting Tempest Therapeutics Inc. trend using moving averages2025 Key Lessons & Capital Efficiency Focused Strategies - Newser
Advanced analytics toolkit walkthrough for Tempest Therapeutics Inc.Weekly Trade Analysis & Consistent Profit Trade Alerts - Newser
Is this a good reentry point in Tempest Therapeutics Inc.Portfolio Return Report & AI Powered Trade Plan Recommendations - Newser
will tempest therapeutics inc. bounce back from current supportNew Guidance & Daily Price Action Insights - Newser
Order flow analysis tools used on Tempest Therapeutics Inc.2025 Dividend Review & Accurate Buy Signal Alerts - Newser
Will Tempest Therapeutics Inc. outperform the marketProfit Target & Accurate Intraday Trading Signals - Newser
Is Tempest Therapeutics Inc. forming a reversal pattern2025 Risk Factors & Daily Stock Trend Watchlist - Newser
Tempest Therapeutics Inc. stock outlook for YEAREarnings Overview Report & Weekly High Potential Stock Alerts - Newser
Using AI based signals to follow Tempest Therapeutics Inc.Quarterly Growth Report & AI Powered Market Entry Ideas - Newser
Custom strategy builders for tracking Tempest Therapeutics Inc.2025 Risk Factors & Daily Chart Pattern Signals - Newser
Analyzing drawdowns of Tempest Therapeutics Inc. with statistical toolsMarket Weekly Review & Verified Chart Pattern Trade Signals - Newser
Using economic indicators to assess Tempest Therapeutics Inc. potential - Newser
Long term hold vs stop loss in Tempest Therapeutics Inc.July 2025 Final Week & Verified Momentum Stock Watchlist - Newser
Is Tempest Therapeutics Inc. a candidate for recovery playOil Prices & Capital Protection Trade Alerts - Newser
Top chart patterns to watch in Tempest Therapeutics Inc.2025 Earnings Impact & Free Long-Term Investment Growth Plans - Newser
Combining price and volume data for Tempest Therapeutics Inc.2025 Pullback Review & Short-Term Trading Opportunity Alerts - Newser
Will Tempest Therapeutics Inc. bounce back from current supportJuly 2025 Volume & Trade Opportunity Analysis - Newser
How to integrate Tempest Therapeutics Inc. into portfolio analysis toolsM&A Rumor & Low Volatility Stock Suggestions - Newser
What indicators show strength in Tempest Therapeutics Inc.Earnings Beat & AI Optimized Trade Strategies - Newser
What data driven models say about Tempest Therapeutics Inc.’s futureJuly 2025 Sentiment & Fast Momentum Entry Tips - Newser
Tempest Therapeutics Inc Stock (TPST) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.93%
0.10%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):